S1624-118

Reported

To require certain civil penalties to be transferred to a fund through which amounts are made available for the Gabriella Miller Kids First Pediatric Research Program at the National Institutes of Health, and for other purposes.

118th Congress Introduced May 16, 2023

At a Glance

Read full bill text

Legislative Progress

Reported
Introduced Committee Passed
Oct 4, 2023

Reported by Mr. Sanders, with an amendment and an amendment …

Oct 4, 2023

Reported by Mr. Sanders, with an amendment and an amendment …

Oct 4, 2023

Reported by Mr. Sanders, with an amendment and an amendment …

Oct 4, 2023

Reported by Mr. Sanders, with an amendment and an amendment …

Oct 4, 2023

Reported by Mr. Sanders, with an amendment and an amendment …

Oct 4, 2023

Reported by Mr. Sanders, with an amendment and an amendment …

Oct 4, 2023

Reported by Mr. Sanders, with an amendment and an amendment …

Oct 4, 2023

Reported by Mr. Sanders, with an amendment and an amendment …

Oct 4, 2023

Reported by Mr. Sanders, with an amendment and an amendment …

Oct 4, 2023

Reported by Mr. Sanders, with an amendment and an amendment …

Summary

What This Bill Does

Requires SEC civil penalties from drug, device, dietary supplement, and cosmetic companies for Foreign Corrupt Practices Act violations to be transferred to the Pediatric Research Initiative Fund.

Who Benefits and How

Pediatric research receives dedicated funding stream. Children benefit from medical research advances. FCPA enforcement contributes to child health.

Who Bears the Burden and How

Drug and cosmetic companies face penalty transfers to research. SEC enforcement tied to pediatric funding. General Treasury receives less penalty revenue.

Key Provisions

  • Transfers FCPA penalties from healthcare/cosmetic companies to pediatric fund
  • Named after Gabriella Miller Kids First Research Act
  • Applies to disgorgement, interest, and monetary sanctions
Model: claude-opus-4
Generated: Jan 10, 2026 18:54

Evidence Chain:

This summary is derived from the structured analysis below. See "Detailed Analysis" for per-title beneficiaries/burden bearers with clause-level evidence links.

Primary Purpose

Directs SEC penalties from drug and cosmetic companies to pediatric research fund

Policy Domains

Healthcare Securities Pediatric Research

Legislative Strategy

"Fund pediatric research from healthcare company penalties"

Bill Structure & Actor Mappings

Who is "The Secretary" in each section?

Domains
Pediatric Research Securities
Actor Mappings
"secretary"
→ Secretary of Treasury

We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.

Learn more about our methodology